文献速递前列腺癌肾癌与肾肿瘤

前列腺癌与实体器官移植:患者管理与结局

Prostate cancer and solid organ transplantation: patient management and outcomes.
PubMed 文献 · BJU Int · 2024-10-09

本研究回顾性分析两家三级中心110例在实体器官移植前后诊断为前列腺癌的患者,移植前诊断45例(41%),移植后诊断65例(59%)。中位随访5.8年与5.3年期间分别有1例(2%)和3例(5%)发生转移,无前列腺癌死亡。作者认为局限性前列腺癌诊断不应排除实体器官移植,移植的存在似乎不显著影响前列腺癌进展风险。

要点

  • 110例实体器官移植合并前列腺癌患者中,移植前诊断45例(41%),移植后诊断65例(59%)。
  • 移植前诊断组中位随访5.8年,1例(2%)发生转移;移植后诊断组中位随访5.3年,3例(5%)发生转移,均无前列腺癌死亡。
  • 作者认为局限性前列腺癌不应排除实体器官移植,移植似乎不显著影响前列腺癌进展风险。

核心结论

  • 作者认为,局限性前列腺癌诊断不应排除实体器官移植,移植的存在似乎不显著影响前列腺癌进展风险。

研究设计与样本

  • 对两家三级中心在实体器官移植前后诊断为前列腺癌的患者进行回顾性分析,共110例。
  • 患者前列腺癌诊断时中位(IQR)年龄62(56.6-67.2)岁,移植时中位(IQR)年龄58.6(52.7-65.3)岁。
  • 肾移植最常见(54%)。
  • 前列腺癌诊断时中位(IQR)前列腺特异性抗原浓度为6.2(4.5-10)ng/mL。
  • 美国泌尿外科协会风险分组分布为低危36%、中危50%、高危14%。

主要发现

  • 45例(41%)患者在移植前诊断前列腺癌,治疗包括根治性前列腺切除术(RP)62%、前列腺放疗(RT)13%、主动监测(AS)18%。
  • 移植前诊断组自前列腺癌诊断起中位(IQR)随访5.8(2.5-10)年,1例(2%)发生转移性疾病。
  • 65例(59%)患者在实体器官移植后诊断前列腺癌,治疗包括AS 29%、RT 45%、RP 15%。
  • 移植后诊断组中位(IQR)随访5.3(1-8.4)年,3例(5%)发生转移性疾病。
  • 无前列腺癌死亡。

临床怎么用

  • 作者认为,局限性前列腺癌诊断不应排除实体器官移植,移植的存在似乎不显著影响前列腺癌进展风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyse the management and outcomes of individuals diagnosed with prostate cancer either before or after organ transplantation, as the impact of organ transplantation and associated immunosuppression on the incidence, progression, and mortality of prostate cancer remains an area of substantial clinical interest and uncertainty. PATIENTS AND METHODS: We conducted a retrospective analysis of patients from two tertiary care centres who had solid organ transplantation and were diagnosed with prostate cancer before or after organ transplantation. Data collected included demographics and clinical information. RESULTS: The cohort consisted of 110 patients with a median (interquartile range [IQR]) age at prostate cancer diagnosis of 62 (56.6-67.2) years and a median (IQR) age at transplantation of 58.6 (52.7-65.3) years. Renal transplantation was the most common (54%). The median (IQR) prostate-specific antigen concentration at prostate cancer diagnosis was 6.2 (4.5-10) ng/mL, and the distribution of American Urological Association risk groups was: low risk, 36%; intermediate risk, 50%; and high risk, 14%. In all, 45 (41%) patients were diagnosed with prostate cancer prior to transplantation. Management included radical prostatectomy (RP; 62%), prostate radiotherapy (RT; 13%), and active surveillance (AS; 18%). During a median (IQR) follow-up of 5.8 (2.5-10) years from prostate cancer diagnosis, one (2%) patient developed metastatic disease. In all, 65 (59%) patients were diagnosed with prostate cancer subsequent to organ transplantation. Management included AS (29%), RT (45%), and RP (15%). During a median (IQR) follow-up of 5.3 (1-8.4) years, three patients (5%) developed metastatic disease. There were no deaths from prostate cancer. CONCLUSION: A diagnosis of localised prostate cancer should not preclude solid organ transplantation, and the presence of a transplant does not appear to substantially impact risk of prostate cancer progression.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lazarovich A, Kristof TW, Steadman S, et al. Prostate cancer and solid organ transplantation: patient management and outcomes. BJU Int. 2024. PMID: 39385314. doi:10.1111/bju.16558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。